Reason for treatment cessation in patients who stopped all first-line b/tsDMARD.
| All First-line | Rituximab | Tocilizumab | Tofacitinib | Abatacept | Adalimumab | Certolizumab | Etanercept | Golimumab | Infliximab |
|---|---|---|---|---|---|---|---|---|---|
| Na = 3383 patients | N = 65 | N = 288 | N = 185 | N = 285 | N = 862 | N = 250 | N = 948 | N = 466 | N = 34 |
| n = 2656 reasons | n = 51 | n = 238 | n = 105 | n = 233 | n = 661 | n = 221 | n = 795 | n = 327 | n = 25 |
| Contraindication, n (%) | 2 (4) | 3 (1) | — | 5 (2) | 11 (2) | 1 (0.5) | 13 (2) | 3 (1) | — |
| Lack of efficacy, n (%) | 10 (20) | 43 (18) | 42 (40) | 88 (38) | 238 (36) | 114 (52) | 256 (32) | 152 (47) | 4 (16) |
| Uncertain, n (%) | 6 (12) | 11 (5) | 4 (4) | 10 (4) | 27 (4) | 3 (1) | 32 (4) | 4 (1) | — |
| Adverse reaction, n (%) | 7 (14) | 30 (13) | 22 (21) | 18 (8) | 78 (12) | 22 (10) | 98 (12) | 22 (7) | 3 (12) |
| Miscellaneous, n (%) | 26 (51) | 151 (63) | 37 (35) | 112 (48) | 307 (46) | 81 (37) | 396 (50) | 146 (45) | 18 (72) |
| Better alternative | 7 (14) | 65 (27) | 9 (9) | 47 (20) | 119 (18) | 30 (14) | 182 (23) | 69 (21) | 12 (48) |
| Completed treatment/no longer required | 13 (26) | 56 (24) | 23 (22) | 40 (17) | 100 (15) | 35 (16) | 109 (14) | 57 (17) | 6 (24) |
| Financial constraints | — | — | 1 (1) | — | — | — | — | — | — |
| No longer available | — | — | — | — | — | — | — | — | — |
| Other | 6 (12) | 25 (11) | 1 (1) | 21 (9) | 69 (10) | 9 (4) | 94 (12) | 16 (5) | — |
| Patient non-adherence | — | 5 (2) | 3 (3) | 4 (2) | 192 (3) | 7 (3) | 11 (1) | 4 (1) | — |